Posted 41 minutes ago
Cost of Care – Community Based Oncology VS Hospital Based Oncology
Community Oncology: High-Quality Care with Lower Total Cost
As cancer care costs continue to rise, community oncology such as Ironwood Cancer & Research Centers plays a critical role in delivering high‑value treatment that reduces financial burden and improves patient access.
Beyond financial relief for payers and patients, community oncology provides highly personalized, accessible care—and is associated with a 29% reduction in avoidable emergency department visits following chemotherapy. Consider the site of service in your next referral to help protect patients from financial toxicity.
Why site of service matters
The Cost of Care Challenge
We face a national healthcare crisis: cancer care costs are accelerating, while consolidation shifts oncology services into hospital outpatient departments. Hospitals often bill substantially more for the same infused cancer drugs and add facility fees that increase overall spending.
By referring patients to independent community oncology practices, you maintain high clinical standards while generating profound cost savings.
What the Data Shows

If commercial payers shifted all infusion care to independent physician offices, the system could realize an estimated $1.28B in annual savings.
Community oncology settings are linked to a 29% reduction in avoidable emergency department visits after chemotherapy.
What You Can Do
Consider site of service when making referrals for infused oncology therapies.
Direct patients to independent community oncology practices when clinically appropriate.
Engage with payers about value-based models that reward quality and total-cost performance.
- Chang J, Karaca-Mandic P, Nikpay S, Jeffery MM. Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs. JAMA Health Forum. 2023;4(6):e231485.
- Florida Cancer Specialists & Research Institute. Evaluating the Site of Service and Oncology Care Costs. n.d.
- Gordan L. Site of Care: The Value of Community Oncology. Payer Exchange Summit: Oncology Payment Reform; 2018.
- Gordan L, Blazer M, Saundankar V. Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics. AJMC. 2019;25(3):e66-e70.
- Gordan L, Blazer M, Saundankar V, et al. Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting. J Onc Practice. 2018;14(12):e729-e738.
- Gordan L, Singh-Bulkan HHN, Warner A, et al. The Role Of Utilizing Community Oncology Care To Decrease Cancer-Related Financial Toxicity. AJPH. 2025;14(1).
- Jung J, Feldman R, Kalidindi Y. The Impact of Integration on Outpatient Chemotherapy Use and Spending in Medicare. Health Economics. 2019;28(4):517-528.
- Khullar D, Casalino LP, Bond AM. Vertical Integration and the Transformation of American Medicine. NEJM. 2024;390(11):965-967.
- Kolodziej MA, Klein I. Private Payers and Cancer Care: Revisiting the Land of Opportunity. JCO Oncology Practice. 2024;20(3):318-322.
- Long R, Mulligan K, Frasco MA, Trish E, Chernew ME. Cui Bono? Misaligned Incentives in the 340B Program. USC Schaeffer Center; 2025.
- Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical Care Costs Associated with Cancer Survivorship in the U.S. CEBP. 2020;29(7):1304-1312.
- Newcomer LN, Perkins MR, Donelan SA. Tying Payment Incentives to Quality Measurement. J Onc Practice. 2013;9(3):119-121.
- Panchal R, Brendle M, Ilham S, et al. Value-based frameworks and pathways in U.S. cancer care. JMCP. 2023;29(9):999-1008.
- Robinson JC, Whaley CM, Brown TT. Price Differences To Insurers For Infused Cancer Drugs… Health Affairs. 2021;40(9):1395-1401.
- Robinson JC, Whaley C, Dhruva SS. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance. NEJM. 2024;390(4):338-345.
- U.S. Government Accountability Office. HEALTH CARE CONSOLIDATION. 2025; GAO-25-107450.
- Xiao R, Ross JS, Gross CP, et al. Hospital-Administered Cancer Therapy Prices for Patients With Private Insurance. JAMA Intern Med. 2022;182(6):603-611.
